Gadopentetate dimeglumine (SH-L-451A)

Animal experiment:

Rats: Twenty-eight rats are anesthetized and midline laparotomy is performed. Animals are divided into four groups: control, ligation of a single mesenteric arcade, ligation of six consecutive arcades, and ligation of the anterior mesenteric artery (analogous to the superior mesenteric artery in humans). A 1.0-mL enteric bolus of gadopentetate dimeglumine diluted with sterile water (1:1) is given via gavage. Magnetic resonance imaging is performed 2 hr after laparotomy and reviewed for the presence of intraperitoneal gadopentetate dimeglumine by two experienced observers. Animals are sacrificed 24 hr after surgery for pathologic examination[3]. Mice: MR lymphography are performed after the subcutaneous injection of gadopentetate dimeglumine (Gd-DTPA) or gadoxetate disodium (Gd-EOB-DTPA) (0.1, 0.5, or 2.0 mmol per mouse) into the right footpad in six healthy mice, and the time courses of contrast enhancement are assessed. Additionally, the lymphatic pathways from two distinct sites are assessed in tandem by interstitial MR lymphography studies[2].

References:

[1]. Gilbert FJ, et al. Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer. J Magn Reson Imaging. 2014 May;39(5):1272-86.
[2]. Sheng F, et al. Interstitial MR lymphography in mice with gadopentetate dimeglumine and gadoxetate disodium. J Magn Reson Imaging. 2011 Feb;33(2):490-7.
[3]. Montalbano JM, et al. Magnetic resonance imaging detection of extraluminal enterally administered gadopentetate dimeglumine in a rat model of intestinal ischemia. Acad Radiol. 1996 Jun;3(6):486-92.